Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults

 Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults

Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults

Shots:

  • The approval is based on P-III EGALITY study results assessing Erelzi (etanercept) vs Enbrel, evaluating its PK, safety and efficacy
  • On 17 Jan, 2019 Sandoz received NOC from Health Canada for Erelzi for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis & improving physical function in adults with PsA, in combination with methotrexate who do not respond to methotrexate as monothx
  • Erelzi (etanercept, biosimilar) is a mAb, available as a pre-filled syringe (PFS) & pre-filled pen (PFP) in 25 mg and 50 mg PFS, approved by Health Canada for moderately to severely active RA & reducing signs and symptoms of moderately to severely active polyarticular JIA in April, 2017

 Click here to read full press release/ article | Ref: Globe News Wire | Image: Pharmacy Boardroom

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post